All In Biotech

Drug Trial Radar · NCT07020221

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

616

Planned (sponsor's estimate)

Start

Jun 24, 2025

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Verastem, Inc.Industry
Sponsor type
Industry
First posted
Jun 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

Conditions

  • Pancreatic Ductal Adenocarcinoma
  • Non Small Cell Lung Cancer
  • Colorectal Cancer
  • Solid Tumor, Adult
  • G12D Mutated KRAS

Interventions

  • VS-7375Drug

    VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.

  • CetuximabDrug

    Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR).

  • Carboplatin + Pemetrexed + PembrolizumabDrug

    A combination therapy regimen used as a first-line treatment for advanced non-squamous non-small cell lung cancer.

  • Gemcitabine + Nab-paclitaxelDrug

    A chemotherapy regimen used for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma.

  • PembrolizumabDrug

    Immunotherapy used as a first-line treatment for advanced non-squamous non-small cell lung cancer.

  • DefactinibDrug

    A potent, selective, reversible inhibitor of focal adhesion kinase that also inhibits proline-rich tyrosine kinase-2

  • MidazolamDrug

    A short-acting benzodiazepine CNS depressant that has sedative, anxiolytic, amnesic, and hypnotic effects.

  • RepaglinideDrug

    A rapid-acting insulin secretagogue used to lower postprandial blood glucose in patients with type 2 diabetes mellitus.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375Time frame: Up to 2.5 years
  2. Part A: To identify the MTD or MFDTime frame: Cycle 1 (each cycle is 21 days)
  3. Part B: To evaluate the preliminary anticancer activity of the optimal VS-7375 regimenTime frame: Up to 2.5 years
  4. Part C: To characterize the safety, tolerability, and AE profile of VS-7375 in combination regimens.Time frame: From enrollment to the end of treatment; an average of 9 months
  5. Part C: To identify a recommended dose for subsequent studies of combination dosed VS-7375.Time frame: Cycle 1 (each cycle is 21 or 28 days)
  6. Part D: To determine the preliminary anticancer activity of the optimal regimen of VS-7375 as identified in Part CTime frame: Up to 2.5 years
  7. Part E: To determine the impact of VS-7375 on the PK of midazolam or repaglinideTime frame: Up to 2.5 years
  8. Part E: To determine the impact of VS-7375 on the PK of midazolam or repaglinideTime frame: 2.5 years
  9. Part E: To characterize the safety, tolerability, and AE profile of VS-7375 administered in combination with CYP3A4 and CYP2C8 substratesTime frame: 2.5 years
  10. Part F: Serial biopsyTime frame: Up to 2.5 years

Locations

22 sites in 4 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York · Recruiting

  • Univ of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Virginia Mason Medical Center

    Seattle, Washington · Recruiting

  • Macquarie University

    Sydney, New South Wales, Australia · Recruiting

  • Peninsula and Southeast Oncology

    Frankston, Victoria, Australia · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Centre d'Essais Precoces en Cancerologie de Marseille (CEPCM)

    Marseille, France · Recruiting

  • Institut Curie

    Paris, France · Recruiting

  • Vall d'Hebron Instituto de Oncología

    Barcelona, Spain · Recruiting

  • START Rioja - Hospital Universitario San Pedro

    Logroño, Spain · Recruiting

  • START Madrid - FJD

    Madrid, Spain · Recruiting

  • START Madrid CIOCC - Hospital HM Sanchinarro

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.